Authors: Erselcan, T Kairemo, KJA Wiklund, TA Hernberg, M Blomqvist, CP Tenhunen, M Bergh, J Joensuu, H

Citation: T. Erselcan et al., Subclinical cardiotoxicity following adjuvant dose-escalated FEC, high-dose chemotherapy, or CMF in breast cancer, BR J CANC, 82(4), 2000, pp. 777-781

Authors: Hernberg, M Pyrhonen, S Muhonen, T

Citation: M. Hernberg et al., Regimens with or without interferon-alpha as treatment for metastatic melanoma and renal cell carcinoma: An overview of randomized trials, J IMMUNOTH, 22(2), 1999, pp. 145-154

Authors: Hernberg, M

Citation: M. Hernberg, Lymphocyte subsets as prognostic markers for cancer patients receiving immunomodulative therapy, MED ONCOL, 16(3), 1999, pp. 145-153

Authors: Vlaykova, T Talve, L Hahka-Kemppinen, M Hernberg, M Muhonen, T Franssila, K Collan, Y Pyrhonen, S

Citation: T. Vlaykova et al., MIB-1 immunoreactivity correlates with blood vessel density and survival in disseminated malignant melanoma, ONCOL-BASEL, 57(3), 1999, pp. 242-252